Drugs / [18F]MNI-1020
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03239561 | Sep 2017 → Apr 2018 | Alzheimer disease | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]MNI-1020 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03239561 ↗ |
| Modality | Diagnostic / imaging agent | “a positron emission tomography (PET) radioligand for imaging tau pathology” NCT03239561 ↗ |
| Route | Intravenous | “Participants will receive a single intravenous bolus injection of \[18F\]MNI-1020” NCT03239561 ↗ |